{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:35Z","timestamp":1792036835817,"version":"4.4.0"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eurofins Viracor Clinical Diagnostics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Human cytomegalovirus (CMV) remains an important pathogen, especially for immunocompromised patients such as solid organ and hematopoietic stem cell recipients. Viral genomic mutations conferring drug resistance are an important impediment to effective CMV management and frequently lead to use of alternative antiviral drugs to treat CMV disease. Methods: Results from 1459 de-identified patient samples with both UL54 and UL97 sequencing results were analyzed for ganciclovir (GCV) and maribavir (MBV) resistance mutations. Genomic sequencing was performed by the Sanger method and resistance mutations were identified by comparison to CMV reference strain AD169. Results: Ganciclovir resistance was identified in 379 of 1459 (25.98%) of the samples tested, with most resistance-conferring mutations present in viral gene UL97. A total of 121 of 1459 (8.29%) samples had MBV resistance mutations, and 84 (69.42%) of the 121 samples with MBV resistance also had GCV resistance mutations. Of the 84 samples with resistance to both MBV and GCV, 35 (41.67%) had a single UL97 mutation conferring resistance to both drugs, either C480F or F342Y. The overall prevalence of C480F was increased relative to an earlier analysis of samples from this reference laboratory. Conclusions: Although a high prevalence of CMV resistance mutations was identified, this must be taken in the context of healthcare providers submitting samples from patients with suspected CMV resistance. Most MBV-resistant samples were also resistant to GCV, suggesting that use of MBV as an alternative to GCV may benefit from genotypic resistance testing to achieve the effective control of CMV disease.<\/jats:p>","DOI":"10.3390\/v17030421","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:46:46Z","timestamp":1741942006000},"page":"421","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual Resistance to Maribavir and Ganciclovir in Transplant Recipients"],"prefix":"10.3390","volume":"17","author":[{"given":"Steven B.","family":"Kleiboeker","sequence":"first","affiliation":[{"name":"Eurofins Viracor Clinical Diagnostics, 18000 West 99th Street, Lenexa, KS 66219, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4-Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hiskey, L., Madigan, T., Ristagno, E.H., Razonable, R.R., and Ferdjallah, A. (2022). Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.1039938"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1034\/j.1399-3062.2001.00004.x","article-title":"Cytomegalovirus drug resistance and clinical implications","volume":"3","author":"Chou","year":"2001","journal-title":"Transpl. Infect. Dis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant\/Refractory Disease","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105623","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antiviral. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/tid.12241","article-title":"Cytomegalovirus antiviral resistance: Characterization of results from clinical specimens","volume":"16","author":"Kleiboeker","year":"2014","journal-title":"Transpl. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105139","DOI":"10.1016\/j.antiviral.2021.105139","article-title":"Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing","volume":"14","author":"Chou","year":"2021","journal-title":"Antiviral. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jcv.2011.12.019","article-title":"Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis","volume":"53","author":"Boivin","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antiviral. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: A French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre","year":"2011","journal-title":"Transplantation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: A single-center retrospective cohort study","volume":"18","author":"Young","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients","volume":"186","author":"Lurain","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tid.12507","article-title":"Resistant cytomegalovirus in intestinal and multivisceral transplant recipients","volume":"18","author":"Timpone","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: Implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for Refractory Cytomegalovirus Infections with or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104616","DOI":"10.1016\/j.antiviral.2019.104616","article-title":"Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection","volume":"172","author":"Chou","year":"2019","journal-title":"Antiviral. Res"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ofac686","DOI":"10.1093\/ofid\/ofac686","article-title":"Maribavir for cytomegalovirus treatment in the real world-not a silver bullet","volume":"10","author":"Fung","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e14259","DOI":"10.1111\/tid.14259","article-title":"Development of cytomegalovirus resistant to maribavir: Real world, real problem?","volume":"26","author":"Kleiboeker","year":"2024","journal-title":"Transpl. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:49Z","timestamp":1760028829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["v17030421"],"URL":"https:\/\/doi.org\/10.3390\/v17030421","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}